Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204078 | 0.77 | KDM4E (0.43) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1615699 | 0.77 | SMN1; SMN2 (0.38) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1649946 | 0.75 | — | — | |
| SCHEMBL17658847 | 0.74 | KDM4E (0.38) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL20350306 | 0.74 | KDM4E (0.41) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL12671613 | 0.73 | KDM4E (0.40) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL13372534 | 0.72 | KDM4E (0.40) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL8388800 | 0.72 | SMN1; SMN2 (0.59) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8388801 | 0.71 | SMN1; SMN2 (0.58) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL14641186 | 0.70 | KDM4E (0.38) | KDM4EALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-9120813-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | VTV THERAPEUTICS LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | VTV THERAPEUTICS LLC | 2015-03-26 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-7906507-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7727983-B2 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANSTECH PHARMA, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | LIPKIN PAMELA | 2010-03-25 | — | — | US | disclosed |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANS TECH. PHARMA. INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | TRANSTECH PHARMA, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | MJALLI ADNAN M | 2007-11-01 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | KDM4E 1477/4885ALDH1A1 1899/4885NPC1 2522/4885 |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | PGF, PTGS1, PTGS2 | KDM4E 2376/4885ALDH1A1 498/4885NPC1 4127/4885 |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | AGER, APP, BACE1 | KDM4E 4005/4885ALDH1A1 3354/4885NPC1 1598/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | KDM4E 2832/4885ALDH1A1 4001/4885NPC1 4565/4885 |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | KDM4E 2666/4885ALDH1A1 102/4885NPC1 2545/4885 |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | GLP1R, GIPR, GCGR | KDM4E 2534/4885ALDH1A1 637/4885NPC1 3242/4885 |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | KDM4E 2666/4885ALDH1A1 102/4885NPC1 2545/4885 |
| US-20100074857-A1 | COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS | PTGER1, PGF, PTGER2 | KDM4E 1666/4885ALDH1A1 534/4885NPC1 4002/4885 |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F9, F3 | KDM4E 1084/4885ALDH1A1 2892/4885NPC1 1384/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | KDM4E 769/4885ALDH1A1 3036/4885NPC1 653/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | KDM4E 4138/4885ALDH1A1 3093/4885NPC1 2378/4885 |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | GLP1R, GPR119, OTC | KDM4E 2722/4885ALDH1A1 91/4885NPC1 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.